The vaccine will protect infants from diphtheria, tetanus, whooping cough and Hib-Meningitis in India, Panacea Biotec said in a filing to BSE.
The product being fully liquid requires no reconstitution, saves time and minimises chances of error, it added.
Panacea Biotec Joint Managing Director Rajesh Jain said: "Panacea Biotec will remain committed to its mission 'Innovation in support of Life' and continue to provide the latest and most affordable preventive and therapeutic care to patients across the globe."
The stock of Panacea Biotec was today trading at Rs 120.50 in the morning trade on BSE, up 4.87 per cent from its previous close.